PMID- 34982184
OWN - NLM
STAT- MEDLINE
DCOM- 20220720
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 71
IP  - 8
DP  - 2022 Aug
TI  - Oral administration of a whole glucan particle (WGP)-based therapeutic cancer 
      vaccine targeting macrophages inhibits tumor growth.
PG  - 2007-2028
LID - 10.1007/s00262-021-03136-7 [doi]
AB  - Although therapeutic cancer vaccines have been gaining substantial ground, the 
      development of cancer vaccines is impeded because of the undegradability of 
      delivery systems, ineffective delivery of tumor antigens and weak immunogenicity 
      of adjuvants. Here, we made use of a whole glucan particle (WGP) to encapsulate 
      ovalbumin (OVA), thereby formulating a novel cancer vaccine. Results from in 
      vitro experiments showed that WGP-OVA not only induced the activation of bone 
      marrow-derived macrophages (BMDMs) including driving M0 BMDM polarization to the 
      M1 phenotype, upregulating the costimulatory molecules and inducing the 
      generation of cytokines, but also facilitated antigen presentation. After oral 
      administration of the WGP-OVA formulation to mice with OVA-expressing tumors, 
      these particles can increase tumor-infiltrating OVA-specific CD8(+) CTLs and 
      repolarize tumor-associated macrophages (TAMs) toward M1-like phenotype, which 
      led to delayed tumor progression. These findings revealed that WGP could serve as 
      both an antigen delivery system and an adjuvant system for promising cancer 
      vaccines.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - He, Liuyang
AU  - He L
AD  - State Key Laboratory of Genetic Engineering, Department of Pharmaceutical 
      Science, School of Life Science, Fudan University, Shanghai, 200433, China.
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China.
FAU - Bai, Yu
AU  - Bai Y
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China.
FAU - Xia, Lei
AU  - Xia L
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China.
FAU - Pan, Jie
AU  - Pan J
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China.
FAU - Sun, Xiao
AU  - Sun X
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China.
FAU - Zhu, Zhichao
AU  - Zhu Z
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China.
FAU - Ding, Jun
AU  - Ding J
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China.
FAU - Qi, Chunjian
AU  - Qi C
AUID- ORCID: 0000-0001-9567-112X
AD  - Medical Research Center, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, Changzhou, 213003, China. qichunjian@njmu.edu.cn.
FAU - Tang, Cui
AU  - Tang C
AD  - State Key Laboratory of Genetic Engineering, Department of Pharmaceutical 
      Science, School of Life Science, Fudan University, Shanghai, 200433, China. 
      tangcui@fudan.edu.cn.
LA  - eng
GR  - 81672799/national natural science foundation of china/
GR  - BE2019651/natural science foundation of jiangsu province/
GR  - BK20200178/natural science foundation of jiangsu province/
PT  - Journal Article
DEP - 20220104
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Glucans)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Administration, Oral
MH  - Animals
MH  - *Cancer Vaccines
MH  - Glucans/pharmacology
MH  - Macrophages
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - *Neoplasms/therapy
MH  - Ovalbumin
PMC - PMC10992519
OTO - NOTNLM
OT  - Cancer vaccine
OT  - Macrophages
OT  - Oral administration
OT  - Whole glucan particle (WGP)
COIS- The authors declare that they have no competing interest.
EDAT- 2022/01/05 06:00
MHDA- 2022/07/22 06:00
PMCR- 2022/01/04
CRDT- 2022/01/04 12:34
PHST- 2021/06/29 00:00 [received]
PHST- 2021/12/20 00:00 [accepted]
PHST- 2022/01/05 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
PHST- 2022/01/04 12:34 [entrez]
PHST- 2022/01/04 00:00 [pmc-release]
AID - 10.1007/s00262-021-03136-7 [pii]
AID - 3136 [pii]
AID - 10.1007/s00262-021-03136-7 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2022 Aug;71(8):2007-2028. doi: 
      10.1007/s00262-021-03136-7. Epub 2022 Jan 4.